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Abstract

The 2010 National Security Strategy states, “The effective dissemination of a
lethal agent would endanger the lives of thousands of people and have unprecedented
economic, societal, and political consequences. We must continue to work at home with
first responders and health officials to reduce the risk associated with high-consequence
threats”. Nerve agents, such as Sarin gas, are considered high consequence threats. The
threat of use of agents such as Sarin is as much a threat today as any other time in our
history. However, the suggested treatment protocol is not as precise as it could be.
Debate exists over the dosing and timing of atropine and oxime treatment when
combating the effects caused by exposure to nerve agents. Oxime treatment has proved
to be less than effective under several situations. The research presented in this paper
used a physiologically based pharmacokinetic model to determine if the current treatment
protocol prescribed by the Center for Disease Control (CDC) and the U.S Army is
effective in treating victims suffering from acute exposure symptoms. Then the model
was used to determine what treatment should be applied to victims suffering from mild
exposure symptoms. The results indicate that the current treatment prescribed by the
CDC and U.S. Army is effective; however treatment with oxime therapy was not
effective in alleviating symptoms for someone suffering from mild exposure. By
applying these results a treatment protocol was developed for someone suffering from
mild exposure symptoms to Sarin gas.
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A SYSTEM DYNAMICS APPROACH TO EFFICACY OF OXIME THERAPY IN
MILD EXPOSURE TO SARIN GAS

I. Introduction

According to the 2010 National Security Strategy, “The effective dissemination of
a lethal agent within a population center would endanger the lives of hundreds of
thousands of people and have unprecedented economic, societal, and political
consequences. We must continue to work at home with first responders and health
officials to reduce the risk associated with high-consequence threats” (National Security
Strategy, 2014:23). The term high consequence threat in this situation deals with
weapons of mass destruction (WMD), nuclear, biological and chemical. While all three
are considered high consequence threats, the use of nerve agents in recent history has
prompted resurgence in the understanding of exactly how horrifying these chemicals can
be when used as weapons. “The Obama administration asserted Sunday for the first time
that the Syrian government used the nerve gas Sarin to kill more than 1,400 people (21
August 2013) in the world’s gravest chemical weapons attack in 25 years ” (Washington
Post, 2014).
While the use of chemical weapons by the military during combat operations is
considered appalling, the use by terrorist groups on the civilian population is even worse.
The most publicized chemical attack by terrorists occurred in Japan in 1994 and 1995 by
religious doomsday sect Aum Shinrikyo. The sect spread Sarin gas in an open area in the
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city of Matsumoto and then later in the Tokyo Subway system (Yanagisawa et al,
1995:290). While not as devastating as planned, the terrifying impacts were felt by
Japan and witnessed by the entire world. Making this an effective terrorist event.
Military professionals and the medical community have not given much thought
to the specter of chemical and biological warfare. The grandfathers and great
grandfathers who fought in World War I are almost all deceased and the horrific image of
gassed soldiers in the trenches of Europe is a distant memory. But forgetting is no longer
a luxury we can afford. Nothing has changed except the increased availability of
chemical and biological weapons (Smart, 1997:12). The recent events in Syria and the
not so distant incident in Japan serve as a reminder of the horrific potential chemical
agents’ posses. Additionally, with the increased threat of asymmetric warfare and radical
groups willing to stop at nothing to promote their agenda, now more than ever, we must
be able to both defend against attack and manage the casualties that might result in such
an attack. Nerve agents, specifically organophosphates, are a threat to both the civilian
and military environment as well as an occupational hazard to workers exposed to
organophosphate based pesticides. The need to educate our healthcare providers on the
proper course of action to take when confronted with causalities that are a direct result of
chemical attack is vital. The education will be at a minimal cost while providing
extraordinary benefits, tangibly measured in the saving of human life.
The treatment of acute poisoning due to chemical warfare agents is of limited
interest to the pharmaceutical industry due to the fact that incidences are rare (Szinicz et
al, 2007:24). Nonetheless, the danger is real and imminent due to the availability and
accessibility in creating chemical agents as a weapon employed by armies or terrorists in
2

an asymmetrical warfare environment. Despite intensive endeavors by the international
community, culminating in the Chemical Weapons Convention that came into force in
1997, highly toxic organophosphorus nerve agents have been stockpiled by different
countries and pose a potential threat to military as well as the civilian population (Worek
et al, 2007:194). Although potent, most nerve agents are relatively short acting and most
are quickly degraded or dispersed to non-lethal concentrations once released. This means
that following an attack there is a high likelihood that emergency services will be able to
rescue a large proportion of exposed victims and transport them to emergency
departments. The ultimate successful recovery of patients from the hot-zone depends
largely upon treatment given within the first few hours (Smart, 1997:82).
One of the reasons that chemical and biological weapons are considered so
dangerous is that the medical community, both civilian and military, have rarely ever
seen patients who have suffered from exposure or have conditions that are similar to
exposure to these agents. Military medical personnel of the United States have not
treated a chemical causality on the battlefield for nearly nine decades and they have never
treated a biological causality (Smart, 1997:11). However, terrorist attacks at home and
abroad have increased the interest of civilian and military health care professionals,
specifically first responders, within the Federal Emergency Management Agency
(FEMA) and the Public Health Service (PHS) that would be required to respond in case
of an attack on our own soil.
The potential use of highly toxic organophosphate-type chemical warfare agents
during military conflicts and by terrorists emphasizes the necessity for the development
of effective medical countermeasures for self and buddy aid as well as for clinical
3

treatment. These agents are relatively simple and inexpensive to make, easy to disperse,
difficult to deter, feared by the public, and have a potential lethality to kill hundreds in
one attack (Smart, 1997:79). Thus nerve agents are the ideal weapon for the terrorist. By
reviewing the work conducted by Holder and Seaman the goal is to test the efficacy of
the treatment regimen prescribed by the U.S. Army and the Center for Disease Control
(CDC). Results of these tests will provide civilian and military medical professionals
with the necessary information to save lives and reduce suffering.
The three widely accepted classes of medication that are effective in the treatment
of nerve agent exposure are anticholinergics, oximes and anticonvulsants (Cannard,
2006:89). The first line of defense and the most commonly used is atropine, which is an
anticholinergic. Atropine works by blocking the effects of excess acetylcholine at
peripheral muscarinic sites (Rebmann et al, 2009:141). However, in high concentrations,
atropine may reduce and then block neuromuscular transmissions, possibly via pre- and
postsynaptic mechanisms (Wali et al, 1987:587). This makes atropine a powerful ally for
first responders. To cope with the respiratory problems, antidotes reactivating inhibited
acetylcholinesterase (AChE) have been developed, formally described as oxime therapy.
Their clinical effectiveness is still a matter of controversy because clearly assessing
oxime effects is both highly complex due to the various microscopic reactions involved
and there are problems in recording the distinct clinical changes. Additionally, seizures
and convulsions are possible due to exposure to nerve agents and these symptoms can be
treated with anticonvulsants. Diazepam is the most commonly prescribed medication for
these symptoms.
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Due to the lack of information on exposure to these agents controversy exists on
the proper treatment, specifically treatment for nerve agents (organophosphates). Debate
exists over the dosing and timing of atropine and oxime treatment when combating the
effects caused by exposure to organophosphates (Karallieddee, 1999:1074). Oxime
treatment has proved to be less than effective under several situations: when the bond
between the organophosphate and AChE has become irreversible, when AChE is bound
by organophosphates in the system faster than it is reactivated or when oxime treatment is
stopped too soon (Szinicz et al, 2007:25). And, once again, due to the low incidence rate
of organophosphate poisoning little research into the development of new treatment
methods has been studied.
Even with the general consensus on the use of these antidotes to mitigate
organophosphate exposure symptoms, several government agencies have varying dosing
strategies (Cannard, 2006:89). Antidotes against chemical warfare agents are "orphan
drugs" given that these poisonings are rare (Szinicz et al, 2007:24). Therefore, they are
of limited interest to the pharmaceutical industry. For this reason, and recognizing the
increasing threat of terrorist or asymmetrical use of chemical warfare agents, the
responsibility for research into medical countermeasures against these weapons is of
primary interest to armies as well as first responders.
In order to test these disparities, physiologically based pharmacokinetic (PBPK)
modeling can be used. The PBPK model is cost-effective, does not require a great deal of
time and eliminates the use of extensive animal testing. The model uses compartments to
describe different tissue groups that have similar pharmacokinetic properties. Several
researchers have applied PBPK modeling to predict levels of organophosphates in human
5

tissue. In 1994, Gearhart and others created the first such PBPK model for two types of
organophosphates (Seaman, 2008:9). The researchers provided evidence that a PBPK
model for organophosphates could be adapted for cross-species studies and across the
family of organophosphorus chemicals (Gearhart et al, 1994:52).
Due to the previously mentioned research, varying treatment guidelines and
questionable effectiveness of oxime treatment lead Seaman to conduct a new study in
2008. Seaman developed a model to predict the concentration of organophosphates,
atropine, oxime, acetylcholine (ACh), AChE and other chemicals in human tissue over
time. In 2011 Holder continued Seaman’s work with the use of PBPK modeling by
further refining the data in order to develop guidance for the timing and dosage strategy
for the treatment of exposure to organophosphates.
The purpose of this work is to provide medical professionals, (military and
civilian), with specific details that may prove vital in alleviating symptoms caused by
exposure to nerve agents, expedite triage procedures and conserve the use of drugs that
maybe ineffective in some scenarios. The ultimate goal is to not only reduce the
mortality rate among the initial victims but also improve the survival rate for those
receiving follow on care.
Research Objectives
1. Validate the PBPK model created by Seaman and then subsequently modified by
Holder and Shelley against prescribed treatment methods set forth by the CDC
and U.S. Army.
2. Determine if oxime therapy is effective in alleviating symptoms for an individual
with mild exposure.
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II. Literature Review
History of Nerve Agents
Weapons combined with chemical agents or chemical agents operating
independently have been part of the evolution of warfare since prehistoric times. The use
of chemicals in warfare has been reported since Greek and Roman times, but it was not
until the 19th century when rapid advances in chemistry and the chemical industry
ushered in the modern era of chemical warfare. With the increased knowledge of their
topological effects came the increased interest from the military. This provided the
perfect nexus for the first employment of weapons of mass destruction during World War
I (WWI). The modern era of chemical warfare was born on 22 April 1915 in the town of
Ypres, Belgium when German troops opened nearly 6000 cylinders of chlorine gas on
opposing French forces (Cannard, 2006:86). The events of WW I surrounding the use of
chemical agents served as the beginning of continuously growing efforts to develop more
effective chemical agents for use in warfare (Szinicz, 2005:168). It was not until more
advanced delivery systems were developed that the possibility for a threat to the civilian
community arose. However, the 1990s witnessed the proliferation of these agents to
terrorist agencies resulting in a common awareness for the necessity to include this threat
in national and international emergency and risk management plans (Szinicz, 2005:173).
The discovery and development of nerve agents was ushered in during the
decades following WW I. As the understanding of the powerful effects of these
chemicals grew so did the development of new weapon variants. The history of nerve
agents began on 23 December 1936 when Dr. Gerhard Schrader of Germany accidently
7

isolated ethyl N, N-dimethylphosphoramidocyanidate, while trying to develop new
insecticides (Cannard, 2006:169). He immediately recognized the potential for military
application and the development of nerve agents as weapons began in earnest. The nerve
agents’ Tabun, Sarin and Soman were developed by Germany, each more powerful than
the previous.
Table 1. Nerve Agent and Lethal Dose
OP Compound

U.S. Army Code

LD50 (µg/kg)

VX

VX

9.15

Soman

GD

34.1

Sarin

GB

44.3

Tabun

GA

117

After World War II (WWII) Germany’s chemical warfare division was exposed
to the North Atlantic Treaty Organization (NATO) and these nerve agents were
sequentially designated as GA (Tabun), GB (Sarin) and GD (Soman), with G for German.
Controlled animal studies of these agents revealed that death could occur within 20
minutes of exposure to very miniscule doses (Somani, 2001:26). In 1952 a British
laboratory discovered another nerve agent, VX (V for venomous), while looking for a
replacement to the insecticide DDT. (Somani, 2001:28). Due to the lethality of VX it
was never employed as insecticide and was produced solely as a nerve agent. VX was
chosen as a promising substance and full scale production commenced in 1961 in the
United States (U.S.). VX appears to be one of the most effective chemical warfare agents
ever produced. The lethal dose for humans is estimated to be about 0.3 mg/person for
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inhalational and 5 mg/person for dermal exposure. Chemical variants were also produced
in the Soviet Union and in China. Sarin and VX became the standard nerve agent in the
USA (Szinicz, 2005:173). The proliferation of these nerve agents continued even though
they are viewed as the most toxic known chemical warfare agents.
Even though the lethality of nerve agents has been well documented they have
rarely been employed in mass during military offensive operations. Even though the
Germans had stock piled tens of thousands of tons of nerve agents they were never used
during WW II (Cannard, 2006:87). Speculation remains, but one of the most popular
arguments is that Hitler was gassed during WW I and knew full well the horrors
associated with the use of these agents of destruction.
Despite the stockpiling of enough nerve agents to kill the world’s population
several times over by the Soviet Union, the first documented use did not occur until the
end of the Iran-Iraq war when the Iraqi Military used them against Iranian forces. Iraq
military used them once again in 1988 when they conducted a chemical attack on their
own people in the town of Halabja, home to 45,000 Iraqi Kurds. Five thousand people
were injured and 200 killed during this attack (Cannard, 2006:87). Since these agents are
relatively simple and inexpensive to make, easy to disperse, and have high lethality to kill
hundreds it can be assumed that they are the perfect weapon for terrorist organizations.
However, it was not until June 1994 and March 1995 that they were employed by a
terrorist organization on the civilian populace. A radical group named Aum Shinrikyo
attempted to spread Sarin gas in an open city, but due to the high level of dispersion of
the nerve agent the attack was not as successful as they had planned. Seven were killed
and 144 were injured (Okumura et al, 1996:130). The group learned from this error and
9

chose a target not as susceptible to changing wind speed and direction, the Tokyo
subway. In March 1995 the group again released Sarin, but this time the effects were
more sinister resulting in 12 deaths and injuring another 5500 (Okumura et al, 1996:130).
Even though the use of nerve agents has been employed only a few times the results have
helped the medical communities create countermeasures that are effective.

Toxic Mechanisms of Organophosphates
The number of accidental, suicidal and homicidal fatalities due to
organophosphorus (OP) compounds is estimated at having surpassed 300,000 per year
worldwide (Eyer et al, 2007:108). A lack of effective treatments, including antidotes, is
considered to contribute to this high mortality rate (Buckley et al., 2004:1231). The
efficacy of current antidotes is largely unproved, and many other potential antidotes have
been developed but are yet to be tested in humans. Meanwhile, preparation for the
terrorist use of organophosphate nerve agents is leading to the stockpiling of large
amounts of these unproved antidotes to treat mass poisoning (Buckley et al., 2004:1232).
Thus, research to improve the therapy of OP poisoning is compulsory.
In order to understand the effects that nerve agents impose on the body it is
important to first provide a brief description of the nervous system and the enzymes
involved in the process. The nervous system has two major subdivisions; the peripheral
(PNS) and the central (CNS). The peripheral has two subdivisions as well, the somatic
and autonomic. The autonomic portion of the nervous system deals with routine
involuntary functions such as digestion, posture, and breathing. The somatic division is
responsible for the voluntary control of body movements via skeletal muscles. The
10

central nervous system is the part of the nervous system that contains the brain and the
spinal cord. It integrates information it receives from, and coordinates and influences the
activity of, all parts of the body (Fox, 2004:175).
Inside the nervous system information flows from one neuron to another across a
synapse, consisting of a pre-synaptic ending that contains neurotransmitters,
mitochondria and other organelles and a postsynaptic ending that contains receptor sites
for neurotransmitters. The space between these is referred to as the synaptic cleft and it
is about 10 nm wide (Fox, 2004:169). Neural transmission across synapses of motor
neurons is a one way action, from the CNS to the receptor. This occurs when
neurotransmitters are released from the pre-synaptic neuron, transmitted across the
synaptic cleft and then received by the post synaptic cell (Fox, 2004:169), Figure 1.
ACh molecules are the most common neurotransmitters in the body and the ones that are
directly affected by organophosphates (Fox, 2004:175).

Figure 1. Synaptic Cleft at Homeostasis (Fox, 2004:169)
The pre-synaptic neurons contain small sacs that store ACh molecules. Once
neural stimulation occurs, the sacs fuse with the membrane of the pre-synaptic neuron
and creates a pore through which the ACh molecules diffuse into the synaptic cleft (Fox,
11

2004:169). Once in the cleft, ACh molecules diffuse across the synapse through
interstitial fluid and briefly bind to receptor sites on the post synaptic cell (Fox,
2004:169). The bind between ACh molecules and the post synaptic receptor sites is the
driving force that stimulates the neural functioning of the post synaptic cell (Fox,
2004:171). ACh molecules will dissociate from the receptor sites and maintain the
potential to re-bind to the receptors for a brief period of time (Fox, 2004:171).
The human body contains two types of cholinergic receptors (having to do with
acetylcholine), the muscarinic and the nicotinic. Both muscarinc and nicotinic receptors
are found in the Central Nervous System and the Peripheral Nervous System. Muscarinic
receptors are responsible for the stimulation of smooth muscles and the exocrine glands
(sweat glands, salivary glands, and mammary glands are examples) as well as action in
the central nervous system. Nicotinic receptors are located in the neuromuscular
junctions of somatic muscles which are part of the peripheral nervous system associated
with the voluntary control of body movements via skeletal muscles (Fox, 2004:154).
AChE are enzymes embedded on the post synaptic cell that terminate the action
of the acetylcholine molecules (Fox, 2004:173). The serine hydroxyl group of the AChE
binds to the acetyl portion of the ACh. When this bind occurs the choline moiety of the
ACh is released and hydrolysis then separates the acetyl moiety from the AChE
(Cannard, 2006:87). The choline moiety will return to the pre-synaptic cell to be
recycled for the creation of new acetylcholine, while the acetyl group will react with
water to form acetic acid (Cannard, 2006:87). Since AChE are the only enzymes that
hydrolyze acetylcholine without their presence ACh will persist in the synaptic cleft and
continually bind and disassociate with the receptor sites and cause excessive neural
12

stimulation (Fox, 2004:173). Overstimulation of these receptors caused by
organophosphate (OP) exposure prevents the coordinated contraction of the muscles,
which in turn leads to spasm and paralysis if not combated early. Symptoms associated
with exposure to OPs include but are not limited to blurred vision, eye pain, headaches,
increased salivation, nausea, vomiting, diarrhea, and bowel or urinary incontinence
(Cannard, 2006:87).
Once in the system nerve agents work their toxic behavior by irreversibly
inhibiting AChE by permanently binding to the enzyme at the esteratic site (Wright,
2009:464), Figure 2. This prevents the normal binding and rapid degradation of ACh by
AChE. Normally, the action of ACh released into the synaptic cleft is terminated by the
enzyme AChE via rapid cleavage of ACh into choline and acetic acid (Cannard,
2006:88). Cholinesterase, i.e. AChE and Butyrylcholinesterase (BuChE), are the main
targets of OP compounds (Worek, 2005:195). The initial response is the persistence of
ACh in the synaptic cleft which causes the action of ACh to be prolonged at the
receptors. This produces the primary effects of nerve agents.

ACh

Nerve Agent Attack

AChE

Post-Synaptic Cell

Pre-Synaptic Cell

OP

Figure 2. Synaptic Cleft with Nerve Agent Present (adapted from Fox, 2004:169)
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After a period of time, which is different for each OP type, the OP-esterase bonds
will mature by the de-alkylation of the OP (Cannard, 2006:89). Once matured, the bond
between OP and esterase becomes irreversible and both the OP and the AChE are
eliminated as active agents. The maturation process is known as aging. Once the aging
process has occurred, AChE levels only recover through the production of new AChE.
Regeneration of AChE is a slow process, occurring at a rate of approximately 1% per day
(Siddel et al, 1997:137).
Nerve agents are OPs, esters of phosphoric acid which are commonly used in
pesticides, flame retardants, lubricating oil additives, plasticizers, softeners and
emulsifiers. Chemically, they are characterized by a central phosphorous atom bound to
an oxygen atom, two alkyl groups and a leaving group (Cannard, 2006:88), Figure 3.

Figure 3. Basic Structure of Nerve Agent (Canard, 2006:87)

Contrary to popular belief, nerve agents are liquids, not gases, but they can be
aerosolized or vaporized during an explosion (Cannard, 2006:87). Thus, the most
common path of exposure is inhalation. This is also the most effective pathway due to
the systemic distribution through the circulatory system. Symptoms typically peak within
15 to 30 minutes after exposure (Cannard, 2006:89).
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Antidote Intentions
The three types of medication widely accepted for the treatment of nerve agent
exposure are anticholinergics, oximes and anticonvulsants. The use and treatment using
anticonvulsants will not be examined in this paper. A patient’s recovery requires
treatment within a few hours of exposure due to the bond that can form between
organophosphates and AChE. After the aging process has occurred, only through the
new production of AChE be restored, which could take months (Cannard, 2006:90).
Atropine is the typical anticholinergic used in the treatment of nerve agent
intoxication. Atropine works by competitively and reversibly blocking Ach binding to
the muscarinic receptor. The presence of atropine reduces the availability of muscarinic
receptors for ACh (Cannard, 2006:92). This will lead to reduced secretion of exocrine
glands and reduces over stimulation of smooth muscles (Cannard, 2006:92).
Additionally, in high concentrations (those given to nerve agent victims) atropine may
reduce and then block neuromuscular transmissions, possibly via pre- and postsynaptic
mechanisms, in both receptor groups (Wali et al, 1987:587). Using atropine as a first
line of defense against nerve agents has been widely accepted and has proven to reduce
the mortality associated with the exposure to organophosphates (Karalliedde, 1999:1075).
The military provides service members with auto injectors, such as the AtroPen in the
Mark I kit. This kit contains 2 mg of atropine and is injected intramuscularly. The
Center for Disease Control (CDC) recommends a dosage on the range between 2-6 mg,
depending on the severity of the exposure. The body will naturally metabolize and
excrete atropine overtime, however at high doses atropine can cause adverse health
effects (USAMRICD, 2007:139).
15

While atropine can help alleviate or even reverse the effects of nerve agent
intoxication, oximes help restore the function at the synaptic cleft. Oximes work by
reactivating AChE that is bound by OPs. In essence the oximes pry the OP off the
AChE. But oximes are only effective prior to the maturation or “aging” of the bond
between OPs and AChE. The half-time aging for tabun, Sarin and VX is between 5 and
48 hours, while soman is only 2-6 minutes. For this reason oxime treatment is useless for
patients exposed to soman (Cannard, 2006:90).
The oxime available in the U.S. is pralidoxime, commonly known as 2-PAM Cl.
It can be administered either by intramuscular injection or intravenously. In order to
counter the aging process it should be administered as quickly as possible to patients with
moderate to severe exposure (Cannard, 2006:90).

Disparity in Treatment methods
While the general types of medications that are beneficial to victims of nerve
agent exposure is generally universally accepted, the specific recommendations as to the
dose and timing vary (Cannard, 2006:91). Acute poisoning with chemical weapons may
induce severe toxicity, requiring immediate therapy, or even cause death. An obvious
life-saving component of poisoning therapy is the use of specific antidotes. But evidence
supporting the efficacy of antidotes in acute poisoning with chemical weapons is lacking
(Szinicz et al, 2007:23). Since these types of poisonings are infrequent, compared to other
forms, there has been little research interest by pharmaceutical companies to develop new
antidotes, but also to confirm the effectiveness of those that are currently available.
Hence, such antidotes are considered “orphan” drugs (Szinicz, 2007:24).
16

There exists a lack of evidence that supports how effective the current treatment
methods for organophosphate exposure are (Szinicz, 2007:24). This is due in large part
to the low incidence rate, but also to the ethics of testing human subjects with nerve agent
exposure. In vitro studies have demonstrated the potential for oximes to be effective, but
in actual practice they have proved to be less than effective and even potentially harmful
(Szinicz, 2007:24).
The World Health Organization (WHO), the Centers for Disease Control and
Prevention (CDC), the U.S. Army Medical Research Institute of Chemical Defense
(USAMRICD), and the New York Department of Health (NYDH) all have published
guidelines for the treatment of nerve agent exposure. Each agency has different
guidelines on the dose and timing of the dose to be administered (Cannard, 2006:91),
Tables 2 and 3.
Table 2. Antidote recommendations for mild/moderate symptoms
(CDC 2010, NYDH 2005, USAMRICD 2007)

Atropine

Pralidoxime

Initial Dose
Repeat Dose

CDC
(field)
2 – 4 mg
2 mg

CDC
(hospital)
2- 4 mg
2 mg

Repeat Interval

5 – 10 min

5 – 10 min

2 – 4 mg
Not
specified
2 – 5 min

Initial Dose
Repeat Dose

600 mg
No
instructions
No
instructions

1000 mg
No
instructions
No
instructions

600 mg
Not
specified
30 – 60 min,
then hourly

Repeat Interval
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NYDH

USAMRICD
(field)
2 mg
2 mg
10 min
600 mg
600 mg
10 min

USAMRICD
(hospital)
2 - 4 mg
No
instructions
No
instructions
600 – 1200 mg
No
instructions
No
instructions

Table 3. Antidote Recommendations for Severe Symptoms
(CDC, 2010; NYDH, 2005; USAMRICD, 2007)

Atropine

Pralidoxime

CDC
(field)
6 mg
2 mg

CDC
(hospital)
6 mg
2 mg

NYDH

Repeat Interval
Initial Dose
Repeat Dose

5 – 10 min
1800 mg
No
instructions

5 – 10 mg
1000 mg
No
instructions

2 – 5 min
1800 mg
Not
specified

Repeat Interval

No
instructions

No
instructions

30 – 60 min,
then hourly

Initial Dose
Repeat Dose

6 mg
Not
specified

USAMRICD
(field)
6 mg
Not applicable,
only 6 mg
carried in field
Not applicable
1800 mg
Not applicable,
only 1800 mg
carried in field
Not applicable

USAMRICD
(hospital)
6 mg
2 mg

3 – 5 min
1800 mg
1000 mg

60 min

What this disparity in treatment has led to in the medical community is a lack of
precise guidance. According to three medical doctors with a history in nerve agent
poisoning, the treatment method is left to the discretion of the attending physician (Burns,
Newmark, Casavant, personal communication, 14 April 2015). While no one would
argue with a trained professional on this highly complex subject it would only seem
logical that at least rudimentary guidelines exist for follow on treatment for someone who
is exposed to nerve agents. Guidelines that should exist, if for no other reason than to
deviate from.
The main area of concern that has been raised from previous studies is in the use
of oxime in the treatment of nerve agent poisoning. These studies even doubt as to how
effective it may be or suggest that it may be harmful (Eddleston et al, 2009:2). A
randomized controlled study conducted by Eddleston and others challenged the efficacy
of pralidoxime in organophosphate insecticide poisoning (Holder, 2011:21). The study
compared the results of a group receiving the WHO recommended dose pralidoxime
(WHO dosing mirrors that of the CDC) against a control group receiving a placebo. It
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was noted that the oxime was successful at reactivating the AChE in the blood compared
to no reactivation in the control group (Eddleston et al, 2009:4). However, despite the
reactivation or potentially because of the reactivation of AChE the researchers found that
the treatment resulted in a 69% increase in mortality (Eddleston et al, 2009:4). The
conclusion from the study was that the dose of oxime recommended by the WHO is most
likely to be ineffective and has the potential to be harmful (Eddleston et al, 2009:4). This
could be in part because the dose level recommended by the WHO is based on level that
is effective in in-vitro studies vice in-vivo studies (Eddleston et al, 2009:5). Based on
these findings this research group recommended further study into the effects of oxime
doses for use in humans as a treatment for nerve agent intoxication.

Physiologically Based Pharmacokinetic (PBPK) Modeling History on
Organophosphate Treatment
The threat of the use of the nerve agents was formerly confined to the military
field and hence easier to anticipate and treat. But events throughout the world have made
this case unjust and thus not a viable option to consider. Due to this fact it is critical to
evaluate medical interventions that may be effective in mass exposures when first
responders and intensive care unit resources are likely to be overwhelmed. In such a
situation, first responders should be able to administer specific first aid. In this situation
antidotes that can be administered with auto injectors by the intramuscular route are
particularly suitable. These antidotes should have a broad spectrum of action (e.g. active
against various OP) along with minimal adverse effects, since they may be administered
in panic situations without poisoning (Eyer et al, 2006:110). The question remains how to
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test the efficacy of those antidotes according to the currently accepted “gold standard” of
evidence-based medicine, without running into inevitable ethical conflicts (Eyer,
2006:110). This can be accomplished through physiologically based pharmacokinetic
(PBPK) modeling.
PBPK modeling calculates the concentrations of chemicals over time in different
tissues of the body, Figure 4. The model contains physiological properties such as tissue
volume, blood flow rate and metabolic pathways. The model then applies mathematical
constructs that allow the coordination of species–specific physiology, chemical-specific
information, and the experimental protocol for the chemical or chemicals of concern.
PBPK models aid scientists and decision makers to simulate the time-course
concentration of chemicals in experimental animals and humans, to better determine
estimates of actual chemical doses delivered to the target tissue, and thereby to provide a
better prediction of response (Gearhart, 2009:791).

Figure 4. Basic PBPK Schematic (Gearhart et al, 1994)
20

Within the model, the organism under study is divided into discrete tissue
compartments with similar physiological and pharmacokinetic properties (Hoang,
1995:101). Mass balance equations are created for each compartment to describe the
concentration of the chemical in those compartments with respect to time. Within each
compartment, binding and bio-transformation of the chemicals will affect the net
accumulation rate of the chemical (Hoang, 1995:101). From this, ordinary differential
equations are created to describe the alteration of chemicals to irrelevant byproducts
through reaction with other chemicals and enzymes (Hoang, 1995:102).
Blood flow provides the medium through which the chemical is distributed. The
product of the fraction of the blood flowing into each compartment, the concentration of
the chemical (mass/volume), and the cardiac output (volume/time) determines the amount
of chemical entering the compartment (mass/time) (Seaman, 2008:24). A partition
coefficient is used to describe the diffusion of the chemical from the tissue compartment
into the venous blood flow. The amount of chemical leaving a compartment (mass/time)
is equal to the product of the fraction of blood flow from the compartment, the cardiac
output (volume/time), the concentration of the chemical in the tissue compartment
(mass/volume), and the inverse of the tissue/blood partition coefficient (Seaman,
2008:25). The compartment coefficient is directly related to outflow: a higher coefficient
equates to slower outflow.
The use of PBPK modeling to estimate the effects of OPs on the human body can
be traced back to a study conducted by Maxwell and others in 1987. This particular
study looked at the inhibition of cholinesterase by soman in various organs and plasma of
rats. During this study the researchers used a multiple regression model to determine the
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extent of cholinesterase inhibition (Holder, 2011:23). From this model it was determined
that blood flow, carboxylesterase and cholinesterase accounted for 94% of the variability
(Maxwell et al, 1987:71). Blood flow accounted for 79% of the variations, leading to the
conclusion that a PBPK model could be used to model the kinetics of soman on in-vivo
cholinesterase inhibition (Maxwell et al, 1987:72).
Gearheart and others took PBPK modeling to the next step in 1994. They
developed a model for organophosphate exposure and AChE inhibition in humans. The
group developed a model to look at two different organophosphates, DFP (an insecticide
known as diisopropylfluorophosphate) and parathion. The model parameters were
derived from in-vivo data from rats and then scaled to humans. The models were
validated by comparing the data collected from the simulation to literature obtained from
exposure to these chemicals (Holder, 2011:26). The conclusion reached was that this
type of model could be used for various types of organophosphates (Gearhart et al,
1994:58).
In 2002 Timchalk and others developed a PBPK model for chlorpyrifos, the
active ingredient in some commercially available pesticides. This study used
experimental data from rats and humans exposed to chlorpyrifos along with literature to
construct a model that exhibited the behavior seen in experimental trials (Holder,
2011:26). Since the model constructed was capable of describing human and rat response
to chlorpyrifos from acute and chronic exposure to a good degree it was concluded that a
PBPK model would be a good starting point for other organophosphate models
(Timchalk et al, 2002:35).
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Worek and others created a model to demonstrate the effectiveness of different
oximes in nerve agent exposure. The team built a model to look at the effectiveness of
the three types of oximes (obidoxime, oxime and HI6) in response to exposure to Sarin,
CycloSarin and VX (Holder, 2011:23). The model was verified by comparing the AChE
levels predicted by the model to in-vivo levels measured in a patient poisoned by
parathion and treated with atropine and obodoxime (Holder, 2011:23). From data
gathered from the model it was determined that the model would be capable of
comparing various oximes, determining effective oxime concentrations, and for
developing oxime treatment for organophosphate poisoning (Worek et al, 2005:195).
In 2008 Seaman and in 2011 Holder continued the use of PBPK modeling to
describe the behavior associated with organophosphate exposure and develop specific
treatment recommendations. Seaman’s research aimed at determining the effectiveness
of the atropine and oxime doses and timing under current prescribed requirements. He
concluded that oximes were more effective when used against less toxic
organophosphates, but less effective, or even deadly, when organophosphates had a very
high toxicity (Seaman, 2008:52). Holder, using Seaman’s work as a starting point
concluded that the use of oximes against strong organophosphates, such as nerve agents,
is ineffective and has the potential to increase the severity of symptoms (Holder,
2011:56). Additionally, he used the data obtained from the model to develop an optimal
dosing strategy that varies significantly from the currently prescribed guidance.
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III. Methodology
Model Configuration
In order to facilitate the functionality of the PBPK model simulations were
performed using Stella 10.0.5 numerical integration software. The model was configured
such that compartments for the pulmonary, arterial, venous, brain, diaphragm, liver, fat,
slowly perfused, richly perfused, thigh and kidney tissues were created. The model
configuration describing absorption, distribution, metabolism and excretion was based
largely on the model developed by Gearhart and others in 1994. The model used for this
simulation process also depicts the behavior of ACh, AChE, BuChE and carboxylesterase
in the compartments previously described. The model structure is illustrated in Figure 4.

Figure 5. PBPK Schematic (Seaman 2008:31)
The model portrays organophosphate absorption through inhalation into the
pulmonary tissue and then distributed through the rest of the system through arterial
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blood flow. Atropine and oxime are introduced via intramuscular injection in the thigh or
through intravenous means. These two compounds are then eliminated by metabolism
via enzymes in the liver or excreted in the urine through the kidneys. ACh and esterase
were produced and degraded in each of the different tissue compartments as well. The
reactions between enzymes and chemicals entering the body occurred within each of the
previously described compartments with the exception of the fat compartment. Since
esterase concentrations were assumed to be negligible or non-existent in fat tissue no
reaction was simulated in the fat compartment (Seaman, 2008:32). Additionally,
degradation of OPs and esterase occurred by maturation of the organophosphate-esterase
bond. Due to the buildup of acetylcholine in the postsynaptic membranes, synapses are
kept in a permanent state of stimulation. With the muscles unable to return to their
natural resting state the most basic of functions are impaired or completely disabled. The
most crucial of all of these functions is respiration. Without the natural respiratory
contraction and relaxation the body is deprived of oxygen. Since respiratory failure is the
leading cause of death in nerve agent victims the diaphragm was singled out as the
compartment within the PBPK model to track for symptoms.

Equations
A complete list of equations used is provided in Appendix A. The PBPK model
works on the premise of a mass balance equation with reactions taking place in each
compartment between the enzymes and chemicals introduced. The equation for this
reaction is shown in equation 1.
Accumulation = 𝐼𝑛 − 𝑂𝑢𝑡 + 𝐺𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 − 𝐶𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛
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(1)

Flow into the system of the chemical agent is achieved through inhalation while
treatment for the symptoms is achieved through intramuscular injection or intravenous
flow into the venous tissue. Outflow from the system is through exhalation, urination and
metabolism. The generation and consumption in the compartments occurs through
natural synthesis as well as degradation and chemical reactions between different
components. The natural synthesis of esterase was zero order and represented by a
synthesis constant. Degradation of esterase was represented by a first order process and
was dependent on the esterase concentration within the compartment (Holder, 2011:31).
The concentration of esterase in each compartment is shown in equation 2.
𝑑(𝐸𝑠𝑡𝑒𝑟𝑎𝑠𝑒)
𝑑𝑡

= 𝑆𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 − 𝐷𝑒𝑔𝑟𝑎𝑑𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 ∗ (𝐸𝑠𝑡𝑒𝑟𝑎𝑠𝑒)

(2)

The reaction between the organophosphate and the esterase is shown in equation 3.
𝑑�

𝐸𝑠𝑡𝑒𝑟𝑎𝑠𝑒
�
𝑂𝑃

𝑑𝑡

= ki(Esterase)(OP) − ks �

Esterase
OP

� − ka(

Esterase

For the previous equation the values of k are defined as:

OP

)

(3)

ki= OP reaction rate coefficient with esterase (mol-1time-1)
ka= OP esterase complex aging reaction rate coefficient (time-1)
ks= OP esterase complex natural separation reaction rate coefficient (time-1)
The chemical reaction between the organophosphates and the esterase with oxime
is shown in equation 4.
d�

Esterase
�
OP

dt

𝐸𝑠𝑡𝑒𝑟𝑎𝑠𝑒

= −𝑘𝑟 �

𝑂𝑃

� 𝑂𝑥𝑖𝑚𝑒

(4)

kr= OP esterase complex reaction rate coefficient with oxime (mol-1time-1)
The interaction between ACh, AChE and atropine is shown in equation 5
(Seaman, 2008:34).
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d(active ACh)
dt

𝑝1

= 𝑝1 �(𝑝2+𝑎𝑡𝑟𝑜𝑝𝑖𝑛𝑒)� − 𝑝2(𝐴𝐶ℎ𝐸)(𝑎𝑐𝑡𝑖𝑣𝑒 𝐴𝐶ℎ)

(5)

= 𝑝1 − 𝑝2(𝐴𝐶ℎ𝐸)(𝑎𝑐𝑡𝑖𝑣𝑒 𝐴𝐶ℎ)

(6)

When atropine is not present the equation simplifies to equation 6.
𝑑(𝑎𝑐𝑡𝑖𝑣𝑒 𝐴𝐶ℎ)
𝑑𝑡

p1=ACh binding rate (mass/time)

p2=ACh degradation constant (time-1)
In order to determine the effectiveness of the treatment an individual is receiving
the model applies a symptom tracking value. This symptom value is used to track the
severity of symptoms as well as the effectiveness of the treatment being received. It is
the ratio of the concentration of the ACh molecules that are actively stimulating the
nerves over the basal concentration of active ACh molecules. At homeostasis the value is
one. When an OP is introduced the ability of AChE to break down ACh is inhibited, thus
overstimulation occurs and the symptom value to a value greater than one. Hence, the
greater the symptom value in the model, the more severe the symptoms. The equation for
the output of the symptom line is shown in equation 7.
𝑑(𝑆𝑦𝑚𝑝𝑡𝑜𝑚𝑠)
𝑑𝑡

𝐴𝐶ℎ 𝑠𝑖𝑡𝑒

= (𝐵𝑎𝑠𝑎𝑙 𝐴𝐶ℎ 𝑆𝑖𝑡𝑒)

(7)

To quantify the symptom value and establish when symptoms first appear and
when death transpires, values were taken from the literature. According to Siddel and
others levels at 10% inhibition would produce mild symptoms, but not to the level that
would require medical attention. Levels above 25% inhibition would require treatment
(Siddel et al, 1997:139). Further guidance is provided by Ashani and Pistinner who state
that when 90% inhibition occurs death is imminent (Ashani and Pistinner, 2004:365).
For the purpose of the symptom value, 10% equates to 1.10 which would be very mild
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symptoms, 25% is 1.25 for the symptom value which would be moderate symptoms that
would require some treatment, and 1.90 would be the level at which death occurs.
The only way medical personnel can determine the severity of exposure is
through visually discerning the clinical signs of the patient. The Agency for Toxic
Substance and Disease Registry (ATSDR) has developed triage procedures for nerve
agent causalities, Table 4. A value of 1.25 for the symptom value would refer to
someone experiencing minimal symptoms and would be triaged with a priority of three.
Likewise 1.90 would be someone that is expectant.
Table 4.Triage Protocol for Nerve Agent Causalities (ATSDR, 2014)

The rationale behind the triage of individuals exposed to a nerve agent in a mass
causality event would be based on symptoms as well as antidote supplies available.
Individuals displaying minimal symptoms would not be treated at the scene, but would be
labeled as minimal and sent to the nearest hospital. The administration of atropine would
most likely not be given to someone displaying these types of symptoms simply based on
the fact that they are not in dire need of treatment to alleviate the symptoms. The
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antidotes would only be given to those suffering from the most severe symptoms with a
likelihood of survival.
The symptom level is directly related to the exposure level. According to the U.S.
Army Medical Research Institute of Chemical Defense (USAMRCD) the levels of
exposure are moderate (MCT), incapacitating (ICT) and lethal (LCT). The
concentrations of these levels are listed in Table 5.
Table 5. Vapor Toxicity (mg-min/m3) (USAMRCD, 2007:129)
Agent
LCT50
ICT50
MCT50
GB(Sarin)

100

75

3

The term Ct is used to describe an estimate of dose. C represents the
concentration of the substance (as vapor or aerosol) in air (usually expressed as mg/m3)
and t represents time (usually expressed in minutes). The Ct value is the product of the
concentration (C) to which an organism is exposed and multiplied by the time (t) during
which it remains exposed to that concentration (Siddel et al, 1997:142).

Assumptions
In attempt to mimic the functions of the human body several assumptions were
made in the model. First, the model assumes instantaneous mixing and equilibrium of the
different chemicals within each of the compartments. Second, metabolism of chemicals
follows Michaelis-Menten kinetics. And lastly, the release of acetylcholine from the presynaptic nerve cell and diffusion of the neurotransmitter across the synaptic cleft is
assumed to be instantaneous and continuous.
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Generation and degradation of AChE is considerably slower than is represented in
this model. AChE regeneration occurs at a rate of 1% per day (Siddel et al, 1997:137).
Due to the extremely slow nature of this regeneration, the parameters for AChE
regeneration were modified to show a more exaggerated version of regeneration in order
to demonstrate the nature of the symptoms over a timeline that is applicable to emergency
room physicians.
Parameters and Coefficients
Parameters and coefficients for this model were obtained from literature or were
retained from the Seaman model of 2008. Sarin data was obtained from a 2005 PBPK
model constructed by Gearhart. The partition coefficients and metabolic parameters
applied in this model provided antidote results that mimicked the observations seen by
Gearhart in his model. A full list of the parameters and coefficients used can be found in
Appendix B. In addition to the aforementioned parameters a kidney elimination constant
of 0.35 was used to produce reasonable elimination results that might be expected from
urine excretion.
The additional values listed in the model to include synthesis rate, and basal levels were
obtained from Gentry and others (Gentry el al, 2002:122). The degradation constants
were obtained from the Seaman model of 2008.

Simulation Protocol
The simulation was broken down into two specific phases. The first phase was
verification. During these simulations the intent was to verify the model was producing
accurate results according to current treatment guidelines as prescribed by the Center for
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Disease Control (CDC) and the U.S. Army. The therapeutic strategies are broken into
two exposure groups, moderate and incapacitating as defined by the Army. The intended
treatment method for both of these obviously varies, but is solely based on symptoms
displayed by the victim.
To verify the model, exposure time remained consistent at 15 minutes. The
exposure started at 5 minutes into the simulation time window and ended at 20 minutes.
Time until treatment was administered varied between 5, 10 and 15 minutes from the
start of the simulation. These timing seemed appropriate for the amount of time it would
take until treatment would be rendered. For each simulation the concentration of Sarin
and duration of exposure (Ct) were recorded as well as time until treatment, amount of
antidote given and the symptom level. For this set of simulations atropine and
pralidoxime were administered intramuscularly at the level currently prescribed by the
CDC and the Army. For the moderate symptoms a dose of 2 mg of atropine and 600 mg
of pralidoxime was simulated. For the more severe symptoms 6 mg atropine and 1800
mg of pralidoxime was simulated. With the prescribed dosing administered the symptom
level was tracked to verify effectiveness of dosing. Maximum symptom levels and
increase or decrease of symptoms was recorded after each simulation.
The second set of simulations examined a scenario in which a victim was exposed
to a relatively low concentration of Sarin and they were displaying moderate symptoms.
The assumption for this scenario is that an individual would be triaged out of the hotzone and taken to a local hospital or military aid station for follow on treatment with only
oxime being administered. The timing for the administration was simulated at 30, 45 and
60 minutes. With the dosing strategy not clearly defined the assumption was made that
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the attending physician may prescribe a prophylactic dose of oxime. The dosing was
simulated at 600 mg and then again at 200 mg in order to determine the effects oxime
therapy would render on an individual displaying moderate symptoms.
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IV. Results and Discussion

A complete list of results achieved for each exposure scenario and treatment applied can
be found in Appendix C. Only simulations found to be most relevant are presented in
this section with a graphical depiction. This section is divided into two segments: Model
Verification and Test for Re-bound of Symptoms.
Model Verification
The model was verified against current treatment protocols that correspond to the
type of symptom level observed to demonstrate that the model is behaving as expected
against scientifically verified parameters. Without proper verification any simulations
that were produced would be met with skepticism regarding the validity of the model.
The intent is to prove that the model is behaving as closely as possible to a human body
when exposed to Sarin gas and the treatment protocol prescribed is effective in
alleviating symptoms.
Due to the fact that the lethality of these agents is known and someone exposed to
these levels would be considered expectant simulations using this level of toxicity was
not applied. For simulation procedures the model was verified against a moderate
exposure (MCT) and an incapacitating exposure (ICT). These levels of exposure are
defined by the U.S. Army. The MCT is any exposure up to 1.5 Ct and the ICT was
anything above a Ct of 1.75. In order to properly run a model based on mathematical
equations correct parameters are invaluable. However, when dealing with actual victims
the concentration one is exposed to will not be known. That is why it is more important
to focus on the symptom level.
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The treatment applied for MCT was 2 mg atropine and 600 mg oxime given via intramuscular injection at time intervals of 15, 20 and 30 minutes into the simulation. Values
graphically displayed are the following: 1. Active AChE levels, 2. Active OP, 3. Oxime
levels, 4. Symptom line, 5. Atropine levels. These times were chosen based on the
assumption that it would take at least those times for someone to receive any treatment.
The ICT followed the same time intervals, but the dosing was increased to 6 mg atropine
and 1800 mg oxime. The dosing strategies are based on CDC and U.S. Army protocol.
1) Simulations 1a, 1b, 1c (MCT): These three simulations tested a very low Ct, 1.5, with
a treatment of both atropine and oxime given at the aforementioned times and the
dosing prescribed for mild symptoms. The symptom line, #4 on the graph, rises as
soon as the Sarin gas is introduced and the AChE levels, line #1, drop accordingly.
As previously mentioned the AChE recovery would not be as rapid as portrayed in
this model, but due to the compressed timeframe intended to be illustrated by this
model recovery happens faster.
a) Administered at 15 minutes: With treatment being administered at 15 minutes
into the simulation the symptom level is fairly low, only reaching a maximum of
1.15 on the symptom line. With such a low symptom level it is debatable wither
or not treatment would be given. But, to demonstrate that the model is behaving
appropriately it was simulated. With such a mild symptom level the treatment
pushes the symptom line below 1. This is due to the action of the atropine
blocking receptor sites and the potential of producing negative results with such a
mild exposure. Although not life threatening the values less than one on the
symptom line would be rapid heartbeat, nausea, dizziness, and lack of sweating.
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Figure 6. Simulation 1a, Moderate Symptoms, Treatment at 15 minutes
Ct(concentration*time)

ExposureTime
(Minutes)

ATROPINE
DOSE/Time

OXIME
DOSE/Time

Symptom
Level Max.

Rebound
Symptom
Max.

1.5=(.1*15)

15

2mg/15 min

600mg/15min

1.15

0

b) Administered at 20 minutes: The symptom line reaches a maximum of 1.2 vice
1.15 for the previous simulation. This would be expected since time until
treatment increased by 5 minutes. The gas has longer time to work its effects on
the body. Again, AChE levels drop as soon as Sarin is introduced but rebounds
once oxime and atropine are applied. Similar to the last simulation the symptom
line drops below 1 due to the mild exposure.
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Figure 7. Simulation 1b, Moderate Symptoms, Treatment at 20 Minutes
Ct(concentration*time)

Exposure Time
(Minutes)

ATROPINE
Dose/Time

OXIME
Dose/Time

Symptom
Level Max.

Rebound
Symptom
Max.

1.5=(.1*15)

15

2mg/20 min

600mg/20 min

1.2

0

c) Administered at 30 minutes: Only difference from the previous two simulations
is the time until the treatment is applied, 30 minutes post exposure. Accordingly,
the symptom line reaches a maximum of 1.25, higher than the previous two which
would be expected. A significant note on this simulation is the drop in AChE
levels once the atropine and oxime are introduced. This is suspected to be the
resurgence of bound Sarin caused by the introduction of the oxime. The oxime
breaks the bond between the Sarin and AChE, thus releasing more unbound Sarin
into the system. However, the symptom line tracks accordingly and begins to
return to the natural state.
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Figure 8. Simulation 1c, Moderate Symptoms, Treatment at 30 Minutes
Ct(concentration*time)

Exposure Time
(Minutes)

ATROPINE
DOSE/Time

OXIME
DOSE/Time

Symptom Level
Max.

Rebound
Symptom
Max.

1.5=(.1*15)

15

2mg/30 min

600mg/30 min

1.25

0

2) Simulations 2a, 2b, 2c (ICT): The Ct was raised to 2.25 for these next three
simulations and accordingly the dosage was increased to the prescribed amount, 6 mg
atropine and 1800 mg oxime.
a) Administered at 15 minutes: As would be expected the symptom line reached a
level that would be considered incapacitating, 1.48. Likewise once the exposure
began the AChE levels dropped. Once treatment was administered the symptom
line began to gradually approach steady state. Thus proving that the treatment is
effective.
Figure 9. Simulation 2a, Incapacitating Symptoms, Treatment at 15 Minutes
Ct(concentration*time)
2.25=(.15*15)

ExposureTime
(Minutes)

ATROPINE
DOSE/Time

15

6mg/15 min
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OXIME DOSE/Time

Symptom Level
Max.

Rebound
Symptom
Max.

1800mg/15min

1.48

0

b) Administered at 20 minutes: The symptom line reached a maximum of 1.75 due
to the fact that treatment was not administered until 20 minutes. Similarly the
AChE levels dropped in response to the exposure to a level considerably lower
than the MCT scenario. This would be expected because the concentration is
greater. Treatment was effective as shown by the symptom line approaching
steady state.
Figure 10. Simulation 2b, Incapacitating Symptoms, Treatment at 20 Minutes
Ct(concentration*time)

ExposureTime
(Minutes)

ATROPINE
DOSE/Time

OXIME
DOSE/Time

Symptom Level
Max.

Rebound
Symptom
Max.

2.25=(.15*15)

15

6mg/20 min

1800mg/20 min

1.75

0

c) Administered at 30 minutes: With the Ct remaining constant but the time until
treatment applied extended out to 30 minutes the symptom line reached a
maximum value of 1.94. With 1.90 being the maximum tolerable limit for
symptoms this threshold was crossed and the victim would have expired.
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Figure 11. Simulation 2c, Incapacitating Symptoms, Treatment at 30 Minutes
Ct(concentration*time)

ExposureTime
(Minutes)

ATROPINE
DOSE/Time

OXIME
DOSE/Time

Symptom Level
Max.

Rebound
Symptom
Max.

2.25=(.15*15)

15

6mg/30 min

1800mg/30 min

1.94

0

Test for Re-Bound in Symptoms
With the model verified it was time to test the hypothesis that the administration of oxime
alone to victims suffering from mild exposure levels may increase the symptoms. Nine
simulations were run all with symptom levels at 38% inhibition of ACh, equating to a
symptom value of 1.38. All simulations were run with treatment being administered at
30, 45 and 60 minutes after initial exposure using the treatment protocol prescribed by
the CDC and U.S. Army for mild exposure victims. These times were chosen based on
the fact the individuals displaying less severe symptoms would not be treated in the hotzone. They would be triaged and then sent off to a medical center to be evaluated and
treated. With the treatment protocol being at the discretion of the physician to treat
symptoms to alleviate suffering only oxime therapy might well be a plausible avenue of
approach.
3) Simulations 3a, 3b, 3c (600mg Intra-Muscular Oxime):
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a) Administered at 30 minutes: Symptom level rebounded by .01. While not a
significant increase it still does represent an increase in symptom level when
symptoms were starting to diminish naturally through the course of time.
However, the symptom level did return to steady state fairly quickly after the
administration of oxime, proving that while not detrimental to recovery the
effectiveness in speeding recovery is questionable at this stage of the simulations.
Figure 12. Simulation 3a, 600mg Oxime IM at 30 Minutes

Ct
(concentration*time)

ExposureTime
(Minutes)

OXIME
DOSE/Time

Symptom
Level Max.

Recovery
Symptom
Level Min.

1.5=(.15*10)

10

600mg/30min

1.38

1.21

Rebound
Symptom
Max.

Rebound
MaxRecovery
Min

Method
of Oxime
Infusion

1.22

0.01

IM

b) Administered at 45 minutes: With the treatment delayed even further the natural
recovery process of the body brought the symptom line down from 1.38 to 1.09,
but as soon as oxime was administered the level rebounded to 1.1. Again, not a
dramatic increase in symptoms, nonetheless an increase.
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Figure 13. Simulation 3b, 600mg Oxime IM at 45 Minutes

Ct(concentration*time)

ExposureTim
e (Minutes)

OXIME
DOSE/Time

Symptom Level
Max.

Recovery
Symptom
Level Min.

Rebound
Sympto
m Max.

Rebound
MaxRecovery
Min

1.5=(.15*10)

10

600mg/45min

1.38

1.09

1.1

0.01

Method
of
Oxime
Infusio
n
IM

c) Administered at 60 minutes: Even after an extended period of time, 60 minutes,
without treatment a slight increase in the symptom line was recorded. The
symptom line naturally recovered to 1.06 and then rebounded to 1.07 when oxime
was administered. While these symptoms levels most likely would not require
treatment of any kind, the proof still remains that symptom levels increased when
oxime was applied.
Figure 14. Simulation 3c, 600mg Oxime IM at 60 Minutes

Ct(concentration*time)

ExposureTime
(Minutes)

OXIME
DOSE/Time

Symptom
Level Max.

Recovery
Symptom
Level Min.

1.5=(.15*10)

10

600mg/60min

1.38

1.06
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Rebound
Symptom
Max.

Rebound
MaxRecovery
Min

Method
of Oxime
Infusion

1.07

0.01

IM

4) Simulations 4a, 4b, 4c (600mg Intra-Venous Oxime): These simulations start the use
of intra-venous administration of oxime therapy applied at the same time intervals as
the previous simulations.
a) Administered at 30 minutes: The symptom level rebounded the most significantly
in this scenario. From a low of 1.21 back up to 1.26. With the oxime hitting the
system faster and at a higher concentration it enabled the release of bound Sarin to
be re-released into the system to cause its damaging effects. At 30 minutes the
levels of bound Sarin in the system would still be relatively high thus causing a
significant spike in symptoms.
Figure 15. Simulation 4a, 600mg Oxime IV at 30 Minutes

Ct(concentration*time)

ExposureTime
(Minutes)

OXIME
DOSE/Time

Symptom
Level Max.

Recovery
Symptom
Level Min.

1.5=(.15*10)

10

600mg/30 min

1.38

1.21

Rebound
Symptom
Max.

Rebound
MaxRecovery
Min

Method
of Oxime
Infusion

1.26

0.05

IV

b) Administered at 45 minutes: As time moves away from exposure and oxime is
administered the symptom rebound starts to decrease.
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Figure 16. Simulation 4b, 600mg Oxime IV at 45 Minutes
Ct(concentration*time)

ExposureTime
(Minutes)

OXIME
DOSE/Time

Symptom
Level Max.

Recovery
Symptom
Level Min.

1.5=(.15*10)

10

600mg/45 min

1.38

1.09

Rebound
Symptom
Max.

Rebound
MaxRecovery
Min

Method of
Oxime
Infusion

1.12

0.03

IV

c) Administered at 60 minutes: No rebound in symptom observed when treatment
was delayed out to 60 minutes. The natural degradation process has had time to
work and alleviate symptoms.
Figure 17. Simulation 4c, 600mg Oxime IV at 60 Minutes
Ct(concentration*time)
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IV

5) Simulations 5a, 5b, 5c (200mg Intra-Venous Oxime): In order to draw an accurate
conclusion as to whether oxime therapy was beneficial or detrimental the dosing of
oxime was lowered to 200 mg with the same time frame for administration. The
results for the lower dose mirror that of the 600 mg intra-venous treatment.
a) Administered at 30 minutes: Symptom levels rebounded by .05, while AChE
levels dropped at the same time and the same level as they did with the 600 mg
application.
Figure 18. Simulation 5a, 200mg Oxime at 30 Minutes
Ct(concentration*time)

ExposureTime
(Minutes)

OXIME
DOSE/Time

Symptom
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Symptom
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Rebound
MaxRecovery
Min
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1.26

0.05

IV

b) Administered at 45 minutes: Symptom levels rebounded by .05, thus proving that
even at a lower dose the use of oxime can produce contrary results.
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Figure 19. Simulation 5b, 200mg Oxime at 45 Minutes
Ct(concentration*time)
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c) Administered at 60 minutes: As previously demonstrated the symptom level
dropped to a level that would not be recognizable. Oxime therapy was still
applied and no increase in symptom levels was recorded.
Figure 20. Simulation 5c, 200mg Oxime at 60 Minutes
Ct(concentration*time)
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V. Conclusion
With the relative ease in which nerve agents are made, the vast quantity that exist
throughout the world and the horrific potential they wield the possibility of an attack on a
military or civilian population seems inevitable. The potential loss of life and suffering
would be staggering and on a scale not frequently witnessed. But with proper procedures
in place the losses can be mitigated. Employing the procedures set forth by the CDC and
U.S. Army the vast majority of exposed patients that arrive at a hospital will survive.
However, the key to survival will be in the triage procedures and the follow on care
provided with limited resources.
The key to the survival of the individuals suffering from the most grave of
symptoms is the expedient treatment with antidotes (atropine and oxime) that may well
be in short supply. By administering these crucial drugs in the prescribed dosing to only
those individuals who truly need it will inevitably save lives and reduce suffering. But
administering these drugs, specifically oxime, to victims displaying moderate symptoms
does not alleviate symptoms and potentially robs that drug from someone who could
benefit from it.
The overall conclusion reached in this research is as follows:
•

The current nerve agent treatment protocol prescribed by the CDC and
U.S. Army is effective in saving lives for those victims experiencing
incapacitating symptom.

•

Oxime therapy alone given to those victims experiencing mild symptoms
is not effective. The recommended treatment for these individuals would
be no oxime therapy administered and potential administration of
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diazepam as a calming agent to treat psychological shock and the
replacement of fluids in the manner the attending physician finds
appropriate.
This minor modification to the treatment protocol will allow attending physicians
to use the limited resources they posses in the most effective manner possible. This will
lead to the ultimate goal, saving as many lives as possible after a nerve agent attack.
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Appendix A. Equations
Organophosphates
Slowly Perfused, Thigh, Diaphragm and Fat Tissues
𝑑𝐶

Ct

𝑉𝑡 𝑑𝑡 = FtQc(Ca − � p �)

Brain, Liver. Kidney and Richly Perfused Tissues

Venous Tissue
𝑉𝑡

Lung Tissue

𝑉𝑡

𝑑𝐶
FtQcCt
VmaxCt
= FtQcCa − �
�−
𝑑𝑡
p
Km + Ct

𝑑𝐶
FtQcCt
VmaxCv
= Qc∑FtCt − QcCv − �
�−
p
Km + Cv
𝑑𝑡
𝑄𝑝𝐶𝑎𝑖𝑟 + 𝑄𝑐𝐶𝑣 =

Arterial Tissue

𝑉𝑎

Oxime

QpCa
+ QcCa
p

𝑑𝐶
VmaxCa
= QcCl − QcCa −
𝑑𝑡
Km + Ca

Brain, Diaphragm, Fat, Richly Perfused, Slowly Perfused Tissue
𝑉𝑡

Kidney Tissue
𝑉𝑡

Liver Tissue

Thigh Tissue

𝑉𝑡

Ct
𝑑𝐶
= FtQc(Ca − )
𝑑𝑡
p

𝑑𝐶
Ct
= FtQc(Ca − − ECa)
𝑑𝑡
p

𝑑𝐶
FtQcCtCt VmaxCt
= FtQcCa −
−
𝑑𝑡
p
Km + Ct
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𝑉𝑡

Venous Tissue

𝑑𝐶
FtQcCtCt
= FtQcCa + IM −
𝑑𝑡
p

𝑉𝑣

Arterial Tissue

𝑑𝐶
= Qc∑FtCt + IV − QcCv
𝑑𝑡
𝑉𝑎

𝑑𝐶
= Qc(Cv − Ca)
𝑑𝑡

Atropine
Brain, Diaphragm, Fat, Richly Perfused, Slowly Perfused Tissues
𝑉𝑡

Kidney Tissue
𝑉𝑡

Liver Tissue
𝑉𝑡

𝑑𝐶
Ct
= FtQc(Ca − )
𝑑𝑡
p

𝑑𝐶
Ct
= FtQc(Ca − − ECa)
𝑑𝑡
p

𝑑𝐶
FtQcCtCt VmaxCt
= FtQcCa −
−
𝑑𝑡
p
Km + Ct

Thigh Tissue

Venous Tissue

𝑉𝑡

𝑑𝐶
FtQcCt
= FtQcCa + IM −
𝑑𝑡
p

𝑉𝑡

𝑑𝐶
= Qc∑FtCt + IV − QcCv
𝑑𝑡
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Arterial Tissue
𝑉𝑎

𝑑𝐶
= Qc(Cv − Ca)
𝑑𝑡

Acetylcholinesterase
Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused and Thigh
Tissue
𝑑𝐶
𝑉𝑡
= X1 − X2CtVt
𝑑𝑡
Butyrylcholinesterase
Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused and Thigh
Tissue
𝑑𝐶
𝑉𝑡
= Y1 − Y2CtVt
𝑑𝑡
Carboxylesterase
Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused and Thigh
Tissue
𝑑𝐶
𝑉𝑡
= Z1 − Z2CtVt
𝑑𝑡
Acetylcholinesterase and Organophosphate Chemical Reaction

𝑑(𝐴𝐶ℎ𝐸)
𝐴𝐶ℎ𝐸
𝐴𝐶ℎ𝐸
= 𝐾𝑖(𝐴𝐶ℎ𝐸)(𝑂𝑃) − 𝐾𝑠 �
� − 𝐾𝑎 �
�
𝑑𝑡
𝑂𝑃
𝑂𝑃

Butyrylcholinesterase and Oganophosphate Chemical Reaction

𝐵𝑢𝐶ℎ𝐸
𝐵𝑢𝐶ℎ𝐸
𝑑(𝐵𝑢𝐶ℎ𝐸)
= 𝐾𝑖(𝐵𝑢𝐶ℎ𝐸)(𝑂𝑃) − 𝐾𝑠 �
� − 𝐾𝑎 �
�
𝑂𝑃
𝑂𝑃
𝑑𝑡

Carboxylesterase and Organophasphate Chemical Reaction

𝑑(𝐶𝑎𝐸)
𝐶𝑎𝐸
𝐶𝑎𝐸
= 𝐾𝑖(𝐶𝑎𝐸)(𝑂𝑃) − 𝐾𝑠 �
� − 𝐾𝑎 �
�
𝑑𝑡
𝑂𝑃
𝑂𝑃

Oxime and Acetylcholinesterase-organophosphate complex chemical reaction
𝑑(𝐴𝐶ℎ𝐸/𝑂𝑃)
𝐴𝐶ℎ𝐸
= 𝐾𝑟(
)(𝑂𝑥𝑖𝑚𝑒)
𝑑𝑡
𝑂𝑃

Oxime and Butyrylcholinesterase-organophosphate complex chemical reaction
𝑑(𝐵𝑢𝐶ℎ𝐸/𝑂𝑃)
𝐵𝑢𝐶ℎ𝐸
= 𝐾𝑟(
)(𝑂𝑥𝑖𝑚𝑒)
𝑑𝑡
𝑂𝑃
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Oxime and Carboxylesterase-organophosphate complex chemical reaction
𝑑(𝐶𝑎𝐸/𝑂𝑃)
𝐶𝑎𝐸
= 𝐾𝑟(
)(𝑂𝑥𝑖𝑚𝑒)
𝑑𝑡
𝑂𝑃

Atropine, Acetylcholine and Acetylcholinesterase reaction

𝑑(𝐴𝐶ℎ 𝑠𝑖𝑡𝑒)
𝑝1
= 𝑝1 �
� − 𝑝2(𝐴𝐶ℎ𝐸)(𝐴𝐶ℎ 𝑠𝑖𝑡𝑒)
𝑝1 + 𝑎𝑡𝑟𝑜𝑝𝑖𝑛𝑒
𝑑𝑡
List of Symbols
Vt: Volume of tissue
dc/dt: Change in chemical concentration with respect to time
Ft: Fraction of blood flow that the tissue
Qc: Cardiac output
Ca: Chemical concentration in arterial tissue
Ct: Chemical concentration in tissue
P: Tissue to blood partition coefficient
Vmax: Maximum metabolism rate
Km: Michaelis-Menton constant
Vv: Volume of venous tissue
Cv: Chemical concentration in venous tissue
Qp: Pulmonary ventilation rate
Cair: Chemical concentration in air
Va: Volume of arterial tissue
Cl: Chemical concentration of blood in lungs
E: Elimination fraction
IM: Intramuscular injection rate
IV: Intravenous injection rate
Ki: Organophosphate reaction rate coefficient with esterase
Ks: Organophosphate-esterase complex natural separation reaction rate coefficient
Ka: Organophophate-esterase complex aging reaction rate coefficient
Kr: Organophosphate-esterase complex reaction rate coefficient with oxime
p1: Acetylcholine binding rate
p2: Acetycholine degradation constant
X1: Acetylcholinesterase synthesis rate
X2: Acetylcholinesterase degradation rate
Y1: Butyrylcholinesterase synthesis rate
Y2: Butyrylcholinesterase degradation rate
Z1: Carboxylesterase synthesis rate
Z2: Carboxylesterase degradation rate
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Appendix B. Parameters
Physiological Parameters
Body Weight
Cardiac Output
Pulmonary Rate

Measurement
60.9kg
302 L/hr
354 L/hr

Source
Gearhart et al.
Gearhart et al.
Gearhart et al.

Blood Flow to Tissue Fractions
Arterial
Brain
Diaphragm
Richly Profused
Fat
Slowly Profused
Thigh
Kidney
Liver
Venous

1
0.134
0.006
0.2
0.036
0.1244
0.0066
0.223
0.27
1

Assumed
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Assumed

Tissue Volume
Arterial
Brain
Diaphragm
Richly Profused
Fat
Slowly Profused
Thigh
Kidney
Liver
Venous

1.218 L
1.303 L
0.183 L
2.089 L
10.353 L
31.899 L
1.681 L
.262 L
2.436 L
3.471 L

Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.

Tissue Normalization Factors
Arterial
Brain
Diaphragm
Rapidly Profused
Fat
Slowly Profused
Thigh
Kidney
Liver

.02 L/kg
.0214 L/kg
.003L/kg
.0343 L/kg
.17 L/kg
.5238 L/kg
.0276 L/kg
.0043 L/kg
.04 L/kg

Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
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Venous

.057 L/kg

Gearhart et al.

Sarin Molecular Weight
Partition Coefficients
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial
Venous

140.1 mg/mmol

Gearhart et al.

0.67
0.77
0.67
17.6
0.77
0.77
1.63
1.53
1
1

Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.

199
440
134
237
51
199

Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.

5467
470
5293
70695
568
16401

Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.
Gearhart et al.

132 mg/mmol

Seaman

0.67
0.77
0.67
17.6
0.77
0.77
1.63

Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman

Metabolic Parameters
KM (Michaelis-Menton)
Arterial
Brain
Kidney
Liver
Rapidly Profused
Venous
VMAX
Arterial
Brain
Kidney
Liver
Rapidly Profused
Venous
Oxime Molecular Weight
Partition Coefficients
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
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Liver
Arterial
Venous
Metabolic Parameters
KM Liver
Vmax Liver
Kidney Partition Parameter
Elimination Partition
Atropine
Molecular Weight
Partition Coefficients
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial
Venous
Metabolic Parameters
KM Liver
Vmax Liver
Kidney Partition Parameter
Elimination Partition
Acetycholinesterase
Molecular Weight
Synthesis Rate
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial

1.53
1
1

Seaman
Seaman
Seaman

700 mg/L
6500 mg/hr

Seaman
Seaman

0.35

Seaman

289 mg/mmol

Seaman

0.67
0.77
0.67
17.6
2.1
2.1
1.63
1.53
1
1

Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman

700 mg/L
6500 mg/hr

Gearhart
Gearhart

0.35

Seaman

320 mg/mmol

Seaman

.00002 umol/hr
.000003 umol/hr
.00003 umol/hr
0.0 umol/hr
.0005 umol/hr
.00002 umol/hr
.000004 umol/hr
.00004 umol/hr
.0001 umol/hr

Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
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Venous
Initial Concentration
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial
Venous
Degradation Constant
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial
Venous
Butyrylcholinesterase
Molecular Weight
Synthesis Rate
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial
Venous
Initial Concentration
Brain
Diaphragm

.0001 umol/hr

Gentry et al.

.04928 umol
.000909 umol
.008314 umol
0.0 umol
.222196 umol
.011708 umol
.000104 umol
.002424 umol
.001212 umol
.003454 umol

Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.

.082508251/hr
.00330033/hr
.003603837/hr
0
.002250266/hr
.001708234/hr
.038461538/hr
.01650165/hr
.08250825/hr
.02895194/hr

Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman

83 mg/mmol

Gearhart et al.

.00002 umol/hr
.000003 umol/hr
.00003 umol/hr
0.0 umol/hr
.0005 umol/hr
.00002 umol/hr
.000004 umol/hr
.00004 umol/hr
.0001 umol/hr
.0001 umol/hr

Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Scaled from Gentry et al.
Gentry et al.

.016859 umol
.002 umol

Gentry et al.
Gentry et al.
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RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial
Venous

.006236 umol
0.0 umol
.190454 umol
.010035 umol
.000782 umol
.019392 umol
.00606 umol
.017271 umol

Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.

Degradation Constant
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial
Venous

.00118631/hr
.0015/hr
.004810776/hr
.004810776/hr
.002625306/hr
.001993024/hr
.00511509/hr
.002062706/hr
.01650165/hr
.005790053/hr

Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman

320 mg/mmol

Known

.00002 umol/hr
.000003 umol/hr
.00003 umol/hr
0.0 umol/hr
.0005 umol/hr
.00002 umol/hr
.000004 umol/hr
.00004 umol/hr
.0001 umol/hr
.0001 umol/hr

Gentry et al.
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Gentry et al.

.778104 umol
.52722 umol
442.73754 umol
0.0 umol
73.007244 umol

Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.

Carboxylesterase
Molecular Weight
Synthesis Rate
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial
Venous
Initial Concentration
Brain
Diaphragm
RPT
Fat
SPT
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Thigh
Kidney
Liver
Arterial
Venous
Degradation Constant
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial
Venous
Acetycholine
Molecular Weight
Activation Rate Constants
Brain
Diaphragm
RPT
SPT
Thigh
Kidney
Liver
Reaction Rate Coefficients
AChE
Ka
Ki
Kr
Ks
BuChE
Ka
Ki
Kr
Ks
CaE

3.846888 umol
4.29957 umol
110.292 umol
5.0904 umol
14.50764 umol

Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.
Gentry et al.

2.57035*10-5/hr
5.69022*10-6/hr
6.77602*10-8/hr
0
6.848864*10-6/hr
5.19901*10-6/hr
9.30326*10-7/hr
3.626674*10-7/hr
1.96448*10-5/hr
6.89292*10-6/hr

Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman
Seaman

146 mg/mmol

Holder

.00719488 mg/hr
.000132714 mg/hr
.001213844 mg/hr
.032440616 mg/hr
.001709368 mg/hr
.000015184 mg/hr
.000353904 mg/hr

Holder
Holder
Holder
Holder
Holder
Holder
Holder

0.1386/hr

Assumed

220000 /mmol(hr)
100/mmol(hr)
1/hr

Assumed
Assumed
Assumed

.054/hr
110000
300/hr
1/hr

Assumed
Assumed
Assumed
Assumed
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Ka
Ki
Kr
Ks
K AcH-AcHE

0
110000/hr
300/hr
1/hr
20292.23826/hr
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Assumed
Assumed
Assumed
Assumed
Assumed

Appendix C. Test Results
Model Verification Mild Symptoms
Exposure
Time
ATROPINE
OXIME
(Minutes)
DOSE/Time
DOSE/Time
5
2mg/15 min
600mg/15min
10
2mg/15 min
600mg/15min
15
2mg/15 min
600mg/15min

TEST
#
1
2
3

Ct(concentration*time)
.75=(.15*5)
1.5=(.15*10)
1.5=(.1*15)

4
5
6

.75=(.15*5)
1.5=(.15*10)
1.5=(.1*15)

5
10
15

2mg/20 min
2mg/20 min
2mg/20 min

7
8
9

.75=(.15*5)
1.5=(.15*10)
1.5=(.1*15)

5
10
15

2mg/30 min
2mg/30 min
2mg/30 min

Symptom
Level
Max.
1
1.14
1.15

Rebound
Symptom
Max.
0
0
0

Recovery
yes
yes
yes

600mg/20 min
600mg/20 min
600mg/20 min

1.03
1.15
1.2

0
0
0

yes
yes
yes

600mg/30 min
600mg/30 min
600mg/30 min

1.04
1.19
1.25

0
0
0

yes
yes
yes

Model Verification Incapacitating Symptoms

Ct(concentration*time)
2.0=(.4*5)
3.0=(.3*10)
2.25=(.15*15)

Exposure
Time
(Minutes)
5
10
15

ATROPINE
DOSE/Time
6mg/15 min
6mg/15 min
6mg/15 min

OXIME
DOSE/Time
1800mg/15min
1800mg/15min
1800mg/15min

Symptom
Level
Max.
1.34
1.41
1.48

Rebound
Symptom
Max.
0
0
0

Recovery
yes
yes
yes

13
14
15

1.75=(.35*5)
2.0=(.2*10)
2.25=(.15*15)

5
10
15

6mg/20 min
6mg/20 min
6mg/20 min

1800mg/20 min
1800mg/20 min
1800mg/20 min

1.62
1.69
1.75

0
0
0

yes
yes
yes

16
17
18

1.75=(.35*5)
2.0=(.2*10)
2.25=(.15*15)

5
10
15

6mg/30 min
6mg/30 min
6mg/30 min

1800mg/30 min
1800mg/30 min
1800mg/30 min

1.62
1.89
1.94

0
0
0

yes
yes
no

TEST
#
10
11
12
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Test for Re-Bound in Symptoms
Recovery
Rebound Method
Symptom Symptom Rebound
Maxof
Level
Level
Symptom Recovery Oxime
TEST
ExposureTime
OXIME
#
Ct(concentration*time)
(Minutes)
DOSE/Time
Max.
Min.
Max.
Min
Infusion
19
1.5=(.15*10)
10
600mg/30min
1.38
1.21
1.2
0.01
IM
20
1.5=(.15*10)
10
600mg/45min
1.38
1.09
1.1
0.01
IM
21
1.5=(.15*10)
10
600mg/60min
1.38
1.06
1.07
0.01
IM
22
23
24

1.5=(.15*10)
1.5=(.15*10)
1.5=(.15*10)

10
10
10

600mg/30min
600mg/45min
600mg/60min

1.38
1.38
1.38

1.21
1.09
1.06

1.26
1.12
n/a

0.5
0.3
n/a

IV
IV
IV

25
26
27

1.5=(.15*10)
1.5=(.15*10)
1.5=(.15*10)

10
10
10

200mg/30min
200mg/45min
200mg/60min

1.38
1.38
1.38

1.21
1.1
1.06

1.26
1.14
n/a

0.5
0.3
n/a

IV
IV
IV
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